Gastric Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastroesophageal Junction Adenocarcinoma (160)

Gastroesophageal Cancer (38)

Gastric Adenocarcinoma (35)

Gastroesophageal Junction Adenocarcinoma (160)

Gastroesophageal Cancer (38)

Gastric Adenocarcinoma (35)

›

HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 2 weeks (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 2wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 2 weeks pembrolizumab Sensitive : A1 Pharmabiz - 2 weeks - (New A1)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 3wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 3 weeks - (New B)
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 3wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 3 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 3wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 3 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 3wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 3 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 3 weeks - (New B)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 3wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 3wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 3wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 3wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 3wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 3wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 3wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 3wk	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) AB011 Sensitive : C2 ASCO-GI 2023 - 3wk	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks AB011 Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 3wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 3wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 3wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 3wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) AB011 Sensitive : C3 ASCO-GI 2023 - 3wk	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks AB011 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 3wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 3wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 3wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 3wk	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 3wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
CAPRIN-1 expression	Gastric Cancer	CAPRIN-1 expression	Gastric Cancer	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 3wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1

Gastric Cancer

Associations(662)

Associations
(662)